Portrait der Gilead Sciences Aktie
Das Unternehmen Gilead Sciences aus USA ist in den Bereichen Chemie & Pharma, Biotechnologie & Pharmazeutika, Biotechnologie, Pharma tätig.
Gilead Sciences ist in mehr als 83 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter iShares Nasdaq US Biotechnology UCITS ETF gewichtet Gilead Sciences mit 7,06% im ETF.
Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Gilead Sciences Anleihen auf einen Blick.
Entdecke die 6 ETFs in denen Gilead Sciences am höchsten gewichtet ist Insgesamt in 83 ETFs enthalten
Dir gefallen die Informationen zu Gilead Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Gilead Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Gilead Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Gilead Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
278 News & Informationen zur Gilead Sciences Aktie
Gilead Sciences: Undervaluation Meets Bullish Chart (NASDAQ:GILD)
Gilead Sciences could move higher in the coming months, from a technical point of view. Click here to read why I believe GILD stock is undervalued.
Gilead Sciences: Bullish Long-Term Prospects (NASDAQ:GILD)
Gilead Sciences' current valuation is very attractive, especially when adjusted for ROCE. Here’s why I believe GILD has double-digit long-term return potential.
TDAM USA Inc. Buys Wells Fargo, Gilead Sciences Inc, Analog Devices Inc, Sells Dow Inc, Apple Inc, The Home Depot Inc
GuruFocus Article or News written by insider and the topic is about:
Rand Paul discloses 16 months late that his wife bought stock in company behind covid treatment. The STOCK Act gives the Justice Department the ability to bring criminal charges, but the bar is high.
Rand Paul’s problematic stock trade Senator Rand Paul admitted this week that he failed to disclose his wife’s purchase of stock in Gilead Sciences …
Stocks That Hit 52-Week Highs On Friday
During Friday's morning session, 137 companies made new 52-week highs.
Areas of Significance: Johnson & Johnson (NYSE:JNJ) was the …
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au…
10 Things in Politics: Biden team's wealth raises ethical concerns
And the number of white people in the US fell for the first time in history.
Rand Paul's wife bought Gilead shares in early days of Covid, the couple's only individual stock purchase in years
GOP Sen. Rand Paul and his wife had not bought stock in an individual company in at least 10 years before Kelley Paul purchased Gilead shares in early 2020.
Business Law Prof Blog
Information about the Law Professor Blogs Network.
William Guyer to join Corcept as Chief Development Officer
MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the…
AOC blasts Congress stock trades … again
Rep. Alexandria Ocasio-Cortez reiterated her belief that members of Congress shouldn't be allowed to trade stocks.
Rand Paul reveals his wife invested in remdesivir parent company Gilead Sciences at the beginning of the pandemic
Congressional members are required to disclose stock trades within 45 days. Rand Paul’s reporting came 16 months late.
2:00PM Water Cooler 8/12/2021
Sen. Rand Paul may have violated insider trading law by failing to disclose wife's COVID drug stock purchases
A watchdog group is asking the Senate Ethics Committee to investigate Paul after his wife purchased stock in an antiviral drug maker in February 2020.
Update: U.S. Companies Making Masks, Vaccines Mandatory
The resurgence of COVID-19 cases in the United States due to the Delta variant and the new guidance from the U.S. Centers for Disease Control and
Hold onto those value stocks because the Wall Street stampede into defensive names is about to turn, says Citi
Follow that crowd? That all depends, says our call of the day.
Factbox-Major U.S. companies making masks, vaccines mandatory By Reuters
Factbox-Major U.S. companies making masks, vaccines mandatory
Veru Sets Another Quarterly Record in Both Net Revenues and
–Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs— –Nine-Month FY21 Year to Date Net…
The Vaccine Project Newsletter: The dog days aren’t over just yet
The Vaccine Project Newsletter: The dog days aren’t over just yet. From PR Week
Gritstone To Host Key Opinion Leader Webinar On Its Neoantigen Oncology Programs
EMERYVILLE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation
BIONTECH : Goldman Sachs sticks Neutral
Goldman Sachs's research confirms his advice and maintains his neutral opinion on the stock. The target price is being increased from USD 173 to USD 433. | August 11, 2021
How Can So Many Lies and So Much Evidence of Fraud and State Murder Be Covered Up? Collective Madness!
Top Stock Reports for Thermo Fisher, McDonald's & Union Pacific
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), McDonald's Corporation (MCD), and Union Pacific Corporation (UNP).
4 Top Healthcare Stocks on the Dow Jones Index
The Dow Jones Industrial Average closed at a record high last week, with stocks tied to economic recovery gaining significantly after a strong jobs re…
+++Coronavirus-Update+++ – Corona: BAG meldet 1910 neue Ansteckungen in der Schweiz – Knapp Hälfte der Bevölkerung vollständig geimpft – Mehr als 6000 Neuinfektionen in Israel – Österreich startet im
Erfahren Sie hier alle aktuellen Entwicklungen zur Coronavirus-Krise, zusammengetragen von der Redaktion von cash.ch.
Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies
– Business combination transaction with BCTG Acquisition Corp., a special purpose acquisition company sponsored by Boxer Capital, completed today …
Black Diamond Therapeutics Announces Appointment Of Mark Velleca, M.D., Ph.D. To Board Of Directors
CAMBRIDGE, Mass. and NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company
NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021
/PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with…
Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights
– Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB)…
+++Coronavirus-Update+++ – Corona: Israel meldet mehr als 6000 Neuinfektionen – Delta-Variante erfasst beinahe halb China – Schweizer Langzeitarbeitslose durch Corona zusätzlich belastet – Krankenhäus
Erfahren Sie hier alle aktuellen Entwicklungen zur Coronavirus-Krise, zusammengetragen von der Redaktion von cash.ch.
Gilead to require U.S. workers receive COVID-19 vaccine
Gilead Sciences Inc said on
Monday it will require all its employees and contractors in the
United States to become vaccinated against COVID-19.
The biotech company's move comes less… | August 9, 2021
Shotgun Blast
To find bloggable cases, we (well, Bexis) read a lot of cases that don’t turn out to be sufficiently significant to be bloggable. Even those cases of…
AlloVir : Reports Second Quarter 2021 Financial Results
– Posoleucel proof-of-concept studies in multi-virus prevention in stem cell transplant patients and BK viremia in kidney transplant patients continue to progress with initial data expected 4Q21
-… | August 6, 2021
Vaccination lowers incidence of covid in organ transplant recipients
'Persons who have received an organ transplant are considered to be at increased risk for covid-19 and for a severe outcome because their immune systems are necessarily suppressed to ensure their transplants are successful and lasting'
Gilead says aware of counterfeit HIV medicines being distributed in U.S.
Gilead Sciences said on Thursday it has become aware that tampered and counterfeit versions of its HIV treatments, Biktarvy and Descovy, are in circulation…
Global $191 Billion Orphan Drugs Markets To 2026: Therapeutic Applications In Rare And Orphan Diseases, Regulatory Framework, Patents, And Innovations
DUBLIN, Aug. 5, 2021 /PRNewswire/ — The
10 Best Biotech Stocks to Buy According to Alan Frazier’s Frazier Healthcare Partners
In this article, we discuss the 10 best biotech stocks to buy according to Alan Frazier.
Gilead Sciences : Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
— Collaboration Leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies —
… | August 5, 2021
Kite And Appia Bio Announce Collaboration To Research And Develop Allogeneic Cell Therapies For Cancer
Kite, a Gilead Company (Nasdaq: GILD), and Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
– INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter…